Boston Scientific (NYSE:BSX) Lowered to Hold Rating by Wall Street Zen

Wall Street Zen cut shares of Boston Scientific (NYSE:BSX) from a buy rating to a hold rating in a research report sent to investors on Friday morning.

A number of other analysts have also issued reports on BSX. Oppenheimer upgraded Boston Scientific from a “market perform” rating to an “outperform” rating and boosted their price target for the company from $118.00 to $125.00 in a report on Monday, September 8th. Leerink Partnrs upgraded Boston Scientific to a “strong-buy” rating in a report on Monday, June 16th. Royal Bank Of Canada reiterated an “outperform” rating and issued a $125.00 price target on shares of Boston Scientific in a report on Monday, September 29th. Canaccord Genuity Group boosted their price target on Boston Scientific from $131.00 to $132.00 and gave the company a “buy” rating in a report on Wednesday. Finally, Barclays boosted their price target on Boston Scientific from $133.00 to $136.00 and gave the company an “overweight” rating in a report on Thursday. Two investment analysts have rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and two have assigned a Hold rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Buy” and a consensus target price of $120.79.

Boston Scientific Stock Up 1.1%

NYSE:BSX opened at $97.30 on Friday. Boston Scientific has a twelve month low of $80.64 and a twelve month high of $109.50. The company has a market cap of $144.17 billion, a price-to-earnings ratio of 57.91, a price-to-earnings-growth ratio of 2.32 and a beta of 0.61. The stock has a fifty day simple moving average of $102.93 and a 200-day simple moving average of $102.05. The company has a current ratio of 1.37, a quick ratio of 0.82 and a debt-to-equity ratio of 0.49.

Boston Scientific (NYSE:BSX) last released its earnings results on Wednesday, July 23rd. The medical equipment provider reported $0.75 earnings per share for the quarter, topping the consensus estimate of $0.72 by $0.03. Boston Scientific had a return on equity of 19.21% and a net margin of 13.55%.The business had revenue of $5.06 billion during the quarter, compared to the consensus estimate of $4.89 billion. During the same period last year, the company earned $0.62 earnings per share. The business’s revenue for the quarter was up 22.8% compared to the same quarter last year. Boston Scientific has set its Q3 2025 guidance at 0.700-0.720 EPS. Analysts anticipate that Boston Scientific will post 2.85 EPS for the current year.

Insiders Place Their Bets

In other news, Director Yoshiaki Fujimori sold 2,901 shares of the company’s stock in a transaction on Tuesday, July 29th. The stock was sold at an average price of $106.99, for a total transaction of $310,377.99. Following the transaction, the director directly owned 2,081 shares of the company’s stock, valued at approximately $222,646.19. This represents a 58.23% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, Director Edward J. Ludwig sold 4,000 shares of the company’s stock in a transaction on Friday, July 25th. The stock was sold at an average price of $106.03, for a total value of $424,120.00. Following the transaction, the director directly owned 18,479 shares in the company, valued at approximately $1,959,328.37. The trade was a 17.79% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders sold 174,214 shares of company stock valued at $17,972,457. Company insiders own 0.50% of the company’s stock.

Hedge Funds Weigh In On Boston Scientific

Several hedge funds have recently made changes to their positions in the company. Vanguard Group Inc. increased its position in shares of Boston Scientific by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 137,134,110 shares of the medical equipment provider’s stock valued at $14,729,575,000 after acquiring an additional 2,545,381 shares during the period. State Street Corp increased its position in shares of Boston Scientific by 1.1% in the 2nd quarter. State Street Corp now owns 65,191,864 shares of the medical equipment provider’s stock valued at $7,002,258,000 after acquiring an additional 713,379 shares during the period. Geode Capital Management LLC increased its position in shares of Boston Scientific by 2.0% in the 2nd quarter. Geode Capital Management LLC now owns 32,424,982 shares of the medical equipment provider’s stock valued at $3,466,320,000 after acquiring an additional 622,602 shares during the period. Norges Bank acquired a new position in shares of Boston Scientific in the 2nd quarter valued at $2,089,937,000. Finally, Invesco Ltd. increased its position in shares of Boston Scientific by 1.4% in the 2nd quarter. Invesco Ltd. now owns 16,851,518 shares of the medical equipment provider’s stock valued at $1,810,022,000 after acquiring an additional 226,578 shares during the period. 89.07% of the stock is owned by institutional investors and hedge funds.

About Boston Scientific

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.